Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon alpha for treatment of chronic myeloid leukemia.
Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Simonsson B, et al. Among authors: bjerrum ow. Curr Drug Targets. 2011 Mar 1;12(3):420-8. doi: 10.2174/138945011794815301. Curr Drug Targets. 2011. PMID: 21143150 Review.
IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. Huuhtanen J, et al. Among authors: bjerrum ow. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585. J Clin Invest. 2022. PMID: 36047494 Free PMC article.
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
El Missiry M, Adnan Awad S, Rajala HL, Al-Samadi A, Ekblom M, Markevän B, Åstrand-Grundström I, Wold M, Svedahl ER, Juhl BR, Bjerrum OW, Haulin I, Porkka K, Olsson-Strömberg U, Hjorth-Hansen H, Mustjoki S. El Missiry M, et al. Among authors: bjerrum ow. J Cancer Res Clin Oncol. 2016 May;142(5):1041-50. doi: 10.1007/s00432-015-2101-4. Epub 2016 Jan 8. J Cancer Res Clin Oncol. 2016. PMID: 26746653
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC. Mikkelsen SU, et al. Among authors: bjerrum ow. Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22. Cancer Med. 2018. PMID: 29932310 Free PMC article. Clinical Trial.
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
Järås M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M, Lassen C, Olofsson T, Bjerrum OW, Richter J, Fioretos T. Järås M, et al. Among authors: bjerrum ow. Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16280-5. doi: 10.1073/pnas.1004408107. Epub 2010 Aug 30. Proc Natl Acad Sci U S A. 2010. PMID: 20805474 Free PMC article.
123 results